NCT02332291View on ClinicalTrials.gov

Connectivity Affecting the Antidepressant REsponse Study

PHASE4CompletedINTERVENTIONAL
Enrollment

95

Participants

Timeline

Start Date

April 30, 2015

Primary Completion Date

August 31, 2020

Study Completion Date

August 31, 2020

Conditions
Major Depressive Disorder
Interventions
DRUG

Escitalopram

Escitalopram 10-20mg daily

DRUG

Bupropion XL

Bupropion XL 150-450mg daily

Trial Locations (1)

37212

Vanderbilt Psychiatric Hospital, Nashville

All Listed Sponsors
lead

Vanderbilt University Medical Center

OTHER

NCT02332291 - Connectivity Affecting the Antidepressant REsponse Study | Biotech Hunter | Biotech Hunter